Novartis with Dynamic Growth in the 2007 First Quarter
PharmaLive.com (press release) - Newtown,PA,USA
Priority late-stage compounds include FTY720 (multiple sclerosis), QAB149 (respiratory diseases), AGO178 (depression), RAD001 (cancer), ABF656 (hepatitis C) ...
See all stories on this topic

Elan Q1 loss seen widening despite sales rise
Therapeutics Daily (subscription) (press release) - Newtown,PA,USA
... on Tuesday thanks to new multiple sclerosis (MS) treatment Tysabri but the cost of the drug's re-launch will mean a widening in the company's loss. ...
See all stories on this topic

STOCK TALK: Aztrazeneca Buys Medimmune. Which Biotech Is Next?
Optionetics - Redwood City,CA,USA
The company’s products include cancer drug Rituxan and Tysabri for multiple sclerosis. It is viewed as a takeover play because it has many of the same ...
See all stories on this topic